Description: Sesen Bio, Inc., a late-stage clinical company, develops next-generation antibody-drug conjugate therapies for patients with cancer. It develops its products based on its Targeted Protein Therapeutics (TPTs) platform. The company's lead product candidate is Vicinium, a fusion protein that is in Phase III clinical trial for the treatment of high-grade non-muscle invasive bladder cancer. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trial for the treatment of high-grade non-muscle invasive bladder cancer; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. In addition, the company is developing systemically-administered TPTs, including VB6-845d for the treatment of solid tumors. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.
Home Page: sesenbio.com
SESN Technical Analysis
245 First Street
Cambridge,
MA
02142
United States
Phone:
617 444 8550
Officers
| Name | Title |
|---|---|
| Dr. Thomas R. Cannell D.V.M. | Pres, CEO & Director |
| Ms. Monica Forbes | CFO & Treasurer |
| Dr. Glen C. MacDonald | Chief Technology Officer |
| Dr. Gregory L. Verdine Ph.D. | Co-Founder |
| Ms. Elly Ryu | Corp. Controller & Principal Accounting Officer |
| Ms. Erin Clark | VP of Corp. Strategy & Investor Relations |
| Mr. Mark R. Sullivan | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
| Mr. Steve Barbera | VP of Market Access |
| Dr. David Brooks | Sr. VP of Clinical Devel. |
| Dr. Dennis Kim M.D., MPH | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.9076 |
| Price-to-Book MRQ: | 0.6445 |
| Price-to-Sales TTM: | 1.7184 |
| IPO Date: | 2014-02-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 17 |